HBV mutation literature information.


  New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H.
 PMID: 25732900       2015       Journal of medical virology
Abstract: Classical lamivudine resistance mutations (rtM204V/rtL180M) were present in one naive-treatment patient infected with genotype G.


  Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
 PMID: 25712861       2015       Journal of medical virology
Abstract: No patient showed mutations that conferred resistance against lamivudine (L180M, M204V/I), adefovir (A181T, N236S), or entecavir (I169M, A184T/V, S202I/G, M250V/I/L).


  High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
 PMID: 25654813       2015       Antiviral therapy
Abstract: Three major patterns of mutations in HBV polymerase gene, namely single (rtM204V), double (rtL180M+rtM204V) and triple (rtV173L+rtL180M+rtM204V) mutations, are associated with 3TC-resistance; additionally, the triple mutation has vaccine-escape potential due to a corresponding change in overlapping surface gene.


  Incidence of natural resistance mutations in naive chronic hepatitis B patients: a systematic review and meta-analysis.
 PMID: 25318660       2015       Journal of gastroenterology and hepatology
Abstract: Mutation rtM204V/I had the highest incidence of 4.89% (95%CI: 4.13-5.65%), and other primary mutations seldom spontaneously occurred.


  Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
 PMID: 25287170       2015       Gut and liver
Abstract: The baseline mutation profiles, rtM204I (p=0.992), rtM204I/V (p=0.177), and rtL180M (p=0.051), were not correlated with the cumulative virological response, and the baseline HBV DNA level (p=0.032) was the only independent predictive factor for cumulative virological response.
Result: Baseline mutation profiles, rtL180M (p=0.051), rtM204I (p=0.992), and rtM204I/V (p=0.177) were not correlated with cumulative virological response (Table 2).
Result: LAM-resistant (rtL180M


  Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
 PMID: 24992206       2015       Antiviral therapy
Abstract: Clonal sequencing identified 13 drug-resistant HBV strains: rtL80I+M204I, rtL80I+M204V, rtL180M+M204I, rtL180M+M204V, rtM204I, rtM204V, rtL80I+L180M+M204I, rtL80I+L180M+


  Establishment of drug-resistant HBV small-animal models by hydrodynamic injection.
 PMID: 26579395       2014       Acta pharmaceutica Sinica. B
Result: compared with wild-type mouse model, viral replication decreases about 10.06-fold in the rtL180M-rtM204V double mutants, but increases about 7.79-fold in the rtL180M-rtM204V-rtV173L triple mutants.
Result: suggesting that rtM204V and rtL180M double mutations in LAM-resistant HBV mutants resulted in the decline of replication ability, but the third compensatory rtV173L mutation significantly increased the HBV replication ab


  A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
 PMID: 25910308       2014       The Turkish journal of gastroenterology
Abstract: The ETVr-related substitution (rtS202P) and lamivudine resistance-related substitutions (rtL180M+rtM204V) were detected by DNA sequencing analysis at week 145.


  [Relationship between hepatitis B virus polymerase gene mutation patterns of rtM204I/V and pre-core/basal core promoter mutations].
 PMID: 25654280       2014       Zhonghua gan zang bing za zhi
Abstract: OBJECTIVE: To investigate the relationship between mutations of rtM204V/I (methionine to valine or isoleucine at position rt204 of reverse transcriptase domain) in the hepatitis B virus (HBV) polymerase gene and the G1896A and G1899A single mutations in the pre-eore (PC) region and the A1762T and G1764A double-mutations in the basal core promoter (BCP) region.


  Genetic insights on host and hepatitis B virus in liver diseases.
 PMID: 25475418       2014       Mutation research. Reviews in mutation research
Abstract: We have described common mutations in the HBV genome (G1896A, rtM204V, rtM204I) which modulate the pathogenesis and carcinogenesis of the liver.



Browser Board

 Co-occurred Entities




   Filtrator